Antitumor activity of gemcitabine hydrochloride loaded lipid polymer hybrid nanoparticles (LPHNs): In vitro and in vivo


YALÇIN T. E. , İLBASMIŞ TAMER S., TAKKA S.

INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol.580, 2020 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 580
  • Publication Date: 2020
  • Doi Number: 10.1016/j.ijpharm.2020.119246
  • Journal Name: INTERNATIONAL JOURNAL OF PHARMACEUTICS
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, Aquatic Science & Fisheries Abstracts (ASFA), BIOSIS, Biotechnology Research Abstracts, CAB Abstracts, EMBASE, International Pharmaceutical Abstracts, MEDLINE, Veterinary Science Database
  • Keywords: Gemcitabine hydrochloride, Lipid polymer hybrid nanoparticles, Pharmacokinetics, Cytotoxicity, Anti-tumor activity, BREAST-CANCER, DELIVERY, NANOMEDICINE, LIPOSOMES, PACLITAXEL, RESISTANCE, DOCETAXEL, THERAPY, RELEASE
  • Gazi University Affiliated: Yes

Abstract

The present study demonstrated the application of gemcitabine hydrochloride (GEM) loaded lipid polymer hybrid nanoparticles (LPHNs) for the enhancement the chemotherapeutic response. GEM, which is an anti-tumor drug, is frequently utilized for the treatment of non-small cell lung cancer, breast cancer and pancreatic cancer. GEM loaded LPHNs were formed and examined for pharmacokinetic profile and in vivo anticancer activity. Modified double emulsion solvent evaporation method was employed in the preparation of the LPHNs. Cytotoxicities of the GEM loaded LPHNs formulation were evaluated on MCF-7 and MDA-MB-231 cells by MTT assays. Pharmacokinetics and in vivo anticancer efficacy studies were conducted following intraperitoneal administration in female Sprague-Dawley rats.